Aligos Therapeutics (ALGS) investor relations material

Development portfolio and financial position

• Pipeline includes pevifoscorvir sodium for chronic HBV, ALG-055009 for MASH/obesity, and ALG-097558 for Covid-19, with multiple candidates in clinical and nonclinical stages.

• NIH and NIAID have awarded $13.8M for Covid-19 protease inhibitor programs.

• Cash, cash equivalents, and investments totaled $77.8M as of 12/31/25, with projected runway into Q3 2026.

Chronic hepatitis B (HBV) market and unmet need

• Approximately 254M people globally live with HBV, causing over 1M deaths annually, mainly from cirrhosis and liver cancer.

• Current treatments (NAs and pegylated interferon) are inadequate, with low rates of functional cure and ongoing disease progression.

• Market opportunity for HBV therapies is estimated at $6.2B by 2031, with significant payor willingness to cover innovative drugs.

Pevifoscorvir sodium clinical profile and efficacy

• Pevifoscorvir sodium is a small molecule CAM-E with picomolar potency, high liver uptake, and a favorable safety profile.

• Demonstrated profound and rapid HBV DNA and RNA reductions in Phase 1, outperforming standard of care in suppression rates.

• No resistance mutations detected after 96 weeks of monotherapy; no viral breakthrough observed.

• Substantial reductions in HBsAg, HBeAg, and HBcrAg in HBeAg+ subjects; meaningful HBcrAg reduction in HBeAg- subjects.

• Favorable safety profile with no serious adverse events leading to discontinuation over 96 weeks.